Apellis Pharmaceuticals/$APLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Ticker
$APLS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
708
Website
APLS Metrics
BasicAdvanced
$2.4B
-
-$1.80
0.66
-
Price and volume
Market cap
$2.4B
Beta
0.66
52-week high
$41.55
52-week low
$16.10
Average daily volume
1.8M
Financial strength
Current ratio
4.08
Quick ratio
3.401
Long term debt to equity
281.707
Total debt to equity
285.936
Interest coverage (TTM)
-4.19%
Profitability
EBITDA (TTM)
-184.418
Gross margin (TTM)
40.56%
Net profit margin (TTM)
-28.83%
Operating margin (TTM)
-24.00%
Effective tax rate (TTM)
-0.60%
Revenue per employee (TTM)
$1,100,000
Management effectiveness
Return on assets (TTM)
-14.20%
Return on equity (TTM)
-103.82%
Valuation
Price to revenue (TTM)
3.095
Price to book
14.75
Price to tangible book (TTM)
14.75
Price to free cash flow (TTM)
-285.452
Free cash flow yield (TTM)
-0.35%
Free cash flow per share (TTM)
-6.75%
Growth
Revenue change (TTM)
48.04%
Earnings per share change (TTM)
-47.94%
3-year revenue growth (CAGR)
112.42%
3-year earnings per share growth (CAGR)
-38.89%
10-year earnings per share growth (CAGR)
-3.31%
What the Analysts think about APLS
Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.
Bulls say / Bears say
Apellis Pharmaceuticals reported $781.4 million in full-year 2024 revenues, representing a 97% year-over-year growth, driven by strong sales of SYFOVRE® and EMPAVELI® (lifesciencereport.com).
The company announced a royalty purchase agreement with Sobi, providing up to $300 million in non-dilutive financing, which strengthens Apellis' balance sheet and supports future growth initiatives (globenewswire.com).
Positive Phase 3 study results for EMPAVELI® in treating C3G and primary IC-MPGN demonstrated sustained efficacy at one year, potentially expanding the drug's market and revenue streams (globenewswire.com).
Apellis Pharmaceuticals faced a setback when the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on pegcetacoplan for treating a rare blood disorder, leading to a share price decline (investing.com).
The company discontinued the open-label extension phase of its MERIDIAN trial for ALS treatment based on external advisors' feedback, indicating challenges in expanding its drug pipeline (biopharmadive.com).
Apellis' stock experienced a significant decline, with shares plunging 4.18% amid regulatory setbacks, reflecting investor concerns over the company's ability to navigate approval processes (ainvest.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
APLS Financial Performance
Revenues and expenses
APLS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apellis Pharmaceuticals stock?
Apellis Pharmaceuticals (APLS) has a market cap of $2.4B as of July 23, 2025.
What is the P/E ratio for Apellis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of July 23, 2025.
Does Apellis Pharmaceuticals stock pay dividends?
No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of July 23, 2025.
When is the next Apellis Pharmaceuticals dividend payment date?
Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Apellis Pharmaceuticals?
Apellis Pharmaceuticals (APLS) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.